Cardio Diagnostics Holdings Inc. Common stock (CDIO) — Analysis Summary
Cardio Diagnostics Holdings Inc. Common stock (CDIO) has a market cap of $5.53M with year-over-year revenue growth of -57.5%. Net margin stands at -43832.5%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed -57.5% year-over-year
- Net margin of -43832.5%
- P/E ratio of -0.9
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, CDIO posted revenue growth of -57.5% and trades at a P/E of -0.9.
Cardio Diagnostics Holdings Inc. Common stock (CDIO)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -525.1x — earnings do not cover interest payments
Operating margin at -44690.7% — severe operating losses
Net margin at -44771.8% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
17
Headquarters
CHICAGO, IL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.